Mabwell (shanghai) Bioscience Co., Ltd. Class ASSE: 688062

Announcement on Voluntary Disclosure of FDA Approval for the Clinical Trial Application for 6MW5311 Injection

· Issued by Mabwell (shanghai) Bioscience Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of FDA Approval for the Clinical Trial Application for 6MW5311 Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis